<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the second-most disabling disease worldwide, and the second most common" exact="neurological disorder." post="Attacks can last many hours or days, and consist"/>
 <result pre="days, and consist of multiple symptoms including headache, nausea, vomiting," exact="hypersensitivity" post="to stimuli such as light and sound, and in"/>
 <result pre="in some cases, an aura is present. Mechanisms contributing to" exact="migraine" post="are still poorly understood. However, transient receptor potential (TRP)"/>
 <result pre="to calcitonin gene-related peptide (CGRP), a neuropeptide strongly implicated in" exact="migraine" post="pathophysiology. Discussion will then focus on recent developments in"/>
 <result pre="in preclinical and clinical studies that implicate TRP channels in" exact="migraine" post="pathophysiology or in the efficacy of therapeutics. Given the"/>
 <result pre="prevalence in reproductive age for both genders [ 2]. Importantly," exact="migraine" post="is the most common severe primary headache, characterized by"/>
 <result pre="sound [ 1]. In current clinical practice, diagnosis of a" exact="migraine" post="is made in accordance to the criteria of the"/>
 <result pre="[ 3], which also allow the homogenous identification of the" exact="migraine" post="phenotype worldwide for research purposes. According to the current"/>
 <result pre="the International Classification of Headache Disorders (ICHD-3) [ 3], the" exact="migraine" post="can be with or without an aura (i.e., transient"/>
 <result pre="Disease (GBD) study, promoted by the World Health Organization, reported" exact="migraine" post="as the most disabling neurological disorder, and the second"/>
 <result pre="the World Health Organization, reported migraine as the most disabling" exact="neurological disorder," post="and the second leading cause of years lived with"/>
 <result pre="causes a significant socio-economic burden. In the European Union, where" exact="migraine" post="is estimated to affect 75 million patients, each year"/>
 <result pre="Migraine: Therapeutics and Pathophysiology Therapeutic options for the treatment of" exact="migraine" post="include drugs for both the attacks, aimed to abort"/>
 <result pre="nortriptyline), but there are also some drugs used only with" exact="migraine" post="prevention objectives, such as flunarizine and pizotifene [ 1]."/>
 <result pre="of onabotulinum toxin A (BoNTA) among the recommended drugs for" exact="migraine" post="prevention, but only for chronic patients [ 6, 7]."/>
 <result pre="only for chronic patients [ 6, 7]. Mechanisms contributing to" exact="migraine" post="are multifactorial, complex, and not yet completely clarified ["/>
 <result pre="that has counter posed the neuronal and the vascular theory," exact="migraine" post="is now considered a neurovascular disorder, with a primary"/>
 <result pre="According to the expression pattern, alpha-CGRP is primarily involved in" exact="migraine" post="pathogenesis. CGRP acts via a G protein-coupled receptor constituted"/>
 <result pre="clinical evidence has accumulated supporting a role of CGRP in" exact="migraine" post="mechanisms. First, CGRP levels are increased during a migraine"/>
 <result pre="in migraine mechanisms. First, CGRP levels are increased during a" exact="migraine" post="attack [ 19] and in chronic migraine patients also"/>
 <result pre="increased during a migraine attack [ 19] and in chronic" exact="migraine" post="patients also in the pain-free interval [ 20], returning"/>
 <result pre="Second, intravenous infusion of CGRP can induce migraine-like attacks in" exact="migraine" post="patients [ 25, 26]. Third, animal data suggest that"/>
 <result pre="a parallel of human photophobia, a phenomenon typically reported during" exact="migraine" post="attack [ 27]. According to the abovementioned evidence, CGRP"/>
 <result pre="Pain While the mechanisms leading to the pain phase of" exact="migraine" post="are unclear, the most likely explanation is that activation"/>
 <result pre="46]. Dilation of meningeal vessels on the headache side during" exact="migraine" post="attacks triggered by cilostazol has recently been found, a"/>
 <result pre="the extracellular events within the tissues themselves that occur during" exact="migraine" post="attacks and the receptors expressed on nociceptors that respond"/>
 <result pre="Reasons for the interest in a TRP channel contribution to" exact="migraine" post="are largely due to their expression on meningeal nociceptors"/>
 <result pre="endogenous and exogenous stimuli that may be of relevance to" exact="migraine" post="attacks ( Figure 1). Further, activation of TRP channels"/>
 <result pre="[ 15, 51, 52]. Given the role of CGRP in" exact="migraine" post="described above, and the as yet unclear mechanism by"/>
 <result pre="number of reviews on the topic of TRP channels and" exact="migraine" post="have been published in recent years documenting the evidence"/>
 <result pre="here, while the focus will be on newer TRP channel" exact="migraine" post="studies. 4.1. TRPV1 Based primarily on preclinical animal studies,"/>
 <result pre="among other factors many of which may be relevant for" exact="migraine" post="[ 48]. TRPV1 was hypothesized to be present on"/>
 <result pre="fibers in the arterial wall of scalp vessels from chronic" exact="migraine" post="patients, where channel expression was higher compared to healthy"/>
 <result pre="[ 61]. Mechanisms leading to increased TRPV1 expression in chronic" exact="migraine" post="patients are unclear, but preclinical studies using repeated 30-day"/>
 <result pre="found increased TRPV1 (and TRPA1) in the trigeminal ganglia, so" exact="migraine" post="itself may upregulate the channel and/or migraine therapeutics may"/>
 <result pre="trigeminal ganglia, so migraine itself may upregulate the channel and/or" exact="migraine" post="therapeutics may also have this potential [ 62]. There"/>
 <result pre="capsaicin-induced meningeal blood flow changes in the presence of diet-induced" exact="obesity" post="[ 63] in mice and suggest a role for"/>
 <result pre="a role for TRPV1 signaling in the increased prevalence of" exact="migraine" post="with obesity (consistent with the increase in capsaicin-induced nociception"/>
 <result pre="for TRPV1 signaling in the increased prevalence of migraine with" exact="obesity" post="(consistent with the increase in capsaicin-induced nociception and photophobia"/>
 <result pre="(consistent with the increase in capsaicin-induced nociception and photophobia with" exact="obesity" post="[ 64]; a similar finding was also seen with"/>
 <result pre="dermal blood flow was seen in female (but not male)" exact="migraine" post="patients compared to controls, suggesting that changes occur in"/>
 <result pre="suggesting that changes occur in TRPV1 fiber neurovascular responses in" exact="migraine" post="[ 67]; similar changes in migraine patients in capsaicin-induced"/>
 <result pre="fiber neurovascular responses in migraine [ 67]; similar changes in" exact="migraine" post="patients in capsaicin-induced dermal blood flow were also recently"/>
 <result pre="by which TRPV1 may be activated in the meninges during" exact="migraine" post="attacks, they only show that the function of the"/>
 <result pre="(CSD), which is thought to be the underlying basis of" exact="migraine" post="aura and has been shown to activate meningeal nociceptors"/>
 <result pre="implicate [ 73] changes in meningeal immune cell function during" exact="migraine" post="as one mechanism of activation of dural nociceptors. Ultimately,"/>
 <result pre="in headache, the TRPV1 antagonist SB-705498 failed in a clinical" exact="migraine" post="study [ 74]. This does not exclude a possibility"/>
 <result pre="74]. This does not exclude a possibility for TRPV1 in" exact="migraine" post="pathology, but it casts serious doubt on selective TRPV1"/>
 <result pre="mechanosensory complex. It is thus interesting in the context of" exact="migraine" post="as headache is known to be influenced by changes"/>
 <result pre="has also been the subject of much interest in the" exact="migraine" post="community, initially based on the repeated identification of single-nucleotide"/>
 <result pre="TRPM8 in migraine. The context of channel activation during native" exact="migraine" post="attacks is not yet clear, so it remains unknown"/>
 <result pre="on a novel TRPM8 antagonist proposed to be tested for" exact="migraine" post="[ 95]. One of the more intriguing studies related"/>
 <result pre="One of the more intriguing studies related to TRPM8 and" exact="migraine" post="in recent years was the finding that the TRPM8"/>
 <result pre="T at chr2:234835093), which has been identified in GWAS of" exact="migraine" post="populations [ 53], is differentially expressed across the Earth"/>
 <result pre="who carry the T;T allele have a higher risk of" exact="migraine" post="than those carrying the rarer versions C;C or C;T"/>
 <result pre="to be predicted by a latitudinal cline, suggesting that human" exact="migraine" post="to the colder climates of Northern Europe introduced positive-selection"/>
 <result pre="climates, lower in warmer climates) matches with the epidemiology of" exact="migraine" post="which shows higher prevalence in Europe, lower prevalence in"/>
 <result pre="(see [ 99, 100, 101]), investigation of this channel in" exact="migraine" post="expanded following a couple of key studies. One was"/>
 <result pre="other key study leading to increased interest in TRPA1 and" exact="migraine" post="was the finding that this channel mediates the vasodilatory"/>
 <result pre="and TRPV1 activation [ 110] and leads to migraine-like cutaneous" exact="hypersensitivity" post="and increased responses of the trigeminal afferent system to"/>
 <result pre="to be complex. NO donors have long been recognized as" exact="migraine" post="triggers, provoking attacks in approximately 75% of patients within"/>
 <result pre="and medulla [ 128]. These studies further implicates TRPA1 in" exact="migraine" post="by directly demonstrating that it plays a role in"/>
 <result pre="by CFA and this is likely to happen by the" exact="suppression" post="of CGRP signalling [ 129]. Notably, it has been"/>
 <result pre="CGRP signalling [ 129]. Notably, it has been shown in" exact="migraine" post="patients that CGRP levels after BoNTA treatment are significantly"/>
 <result pre="the TRPA1 agonist acrolein in a rodent model of chronic" exact="migraine" post="[ 111]. Together, these studies support the concept that"/>
 <result pre="There is currently a great deal of excitement in the" exact="migraine" post="field due to the approval of several, new CGRP-based"/>
 <result pre="regarding the viability of TRP channels as drug targets for" exact="migraine" post="and these questions require additional work among the research"/>
 <result pre="with an agonist. Little work currently exists surrounding TRPV4 and" exact="migraine" post="and this is the area that needs to most"/>
 <result pre="exposure to endogenous substances, reactive oxygen species, environmental irritants, and" exact="migraine" post="triggers such as NO donors as well as its"/>
 <result pre="Taken together, the data currently available surrounding TRP channels and" exact="migraine" post="continue to make a compelling case for further development"/>
 <result pre="Sex differences in the epidemiology, clinical features, and pathophysiology of" exact="migraine" post="Lancet Neurol. 2019 16 76 87 3. collab: Headache"/>
 <result pre="Doan L.P. et al. Global, regional, and national burden of" exact="migraine" post="and tension-type headache, 1990-2016: A systematic analysis for the"/>
 <result pre="W.P. et al. Genome-wide association analysis identifies susceptibility loci for" exact="migraine" post="without aura Nat. Genet. 2012 44 777 782 10.1038/ng.2307"/>
 <result pre="9. Borsook D. Maleki N. Becerra L. McEwen B. Understanding" exact="migraine" post="through the lens of maladaptive stress responses: A model"/>
 <result pre="al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for" exact="migraine" post="Nat. Genet. 2016 48 856 866 10.1038/ng.3598 27322543 12."/>
 <result pre="Warfvinge K. Krause D.N. CGRP as the target of new" exact="migraine" post="therapies—Successful translation from bench to clinic Nat. Rev. Neurol."/>
 <result pre="Palumbo R. Vasoactive peptide levels in the plasma of young" exact="migraine" post="patients with and without aura assessed both interictally and"/>
 <result pre="CGRP levels in peripheral blood as a biomarker for chronic" exact="migraine" post="Neurology 2013 81 1191 1196 10.1212/WNL.0b013e3182a6cb72 23975872 21. Goadsby"/>
 <result pre="Vasoactive peptide release in the extracerebral circulation of humans during" exact="migraine" post="headache Ann. Neurol. 1990 28 183 187 10.1002/ana.410280213 1699472"/>
 <result pre="trigeminal vasoactive peptides in internal jugular vein blood during spontaneous" exact="migraine" post="attacks Cephalalgia 2000 20 907 918 10.1046/j.1468-2982.2000.00146.x 11304026 24."/>
 <result pre="parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and" exact="migraine" post="headache during nitroglycerin induced migraine attack Cephalalgia 2005 25"/>
 <result pre="gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced" exact="migraine" post="attack Cephalalgia 2005 25 179 183 10.1111/j.1468-2982.2005.00836.x 15689192 25."/>
 <result pre="migraine: Regional cerebral blood flow and blood flow velocity in" exact="migraine" post="patients J. Headache Pain 2008 9 151 157 10.1007/s10194-008-0036-8"/>
 <result pre="M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with" exact="migraine" post="with aura Cephalalgia 2010 30 1179 1186 10.1177/0333102410368444 20855363"/>
 <result pre="Role of calcitonin gene-related peptide in light-aversive behavior: Implications for" exact="migraine" post="J. Neurosci. 2009 29 8798 8804 10.1523/JNEUROSCI.1727-09.2009 19587287 28."/>
 <result pre="receptor antagonist BIBN 4096 BS for the acute treatment of" exact="migraine" post="N. Engl. J. Med. 2004 350 1104 1110 10.1056/NEJMoa030505"/>
 <result pre="Randomized, controlled trial of telcagepant for the acute treatment of" exact="migraine" post="Neurology 2009 73 970 977 10.1212/WNL.0b013e3181b87942 19770473 31. Voss"/>
 <result pre="double-blind, placebo-controlled trial of ubrogepant for the acute treatment of" exact="migraine" post="Cephalalgia 2016 36 887 898 10.1177/0333102416653233 27269043 32. Hewitt"/>
 <result pre="the CGRP receptor antagonist MK-3207 in the acute treatment of" exact="migraine" post="Cephalalgia 2011 31 712 722 10.1177/0333102411398399 21383045 33. Marcus"/>
 <result pre="R. Sensitization of the trigeminovascular pathway: Perspective and implications to" exact="migraine" post="pathophysiology J. Cl.in Neurol. 2012 8 89 99 10.3988/jcn.2012.8.2.89"/>
 <result pre="de Koning P.J.H. Larsson H.B.W. Ashina M. Meningeal contribution to" exact="migraine" post="pain: A magnetic resonance angiography study Brain 2019 142"/>
 <result pre="M.H. Dodick D.W. Porreca F. Targeting TRP channels for novel" exact="migraine" post="therapeutics ACS Chem. Neurosci. 2014 5 1085 1096 10.1021/cn500083e"/>
 <result pre="S. De Cesaris F. CGRP receptors and TRP channels in" exact="migraine" post="J. Headache Pain 2015 16 A21 10.1186/1129-2377-16-S1-A21 28132367 55."/>
 <result pre="Lupi C. Geppetti P. TRPA1 and other TRP channels in" exact="migraine" post="J. Headache Pain 2013 14 71 10.1186/1129-2377-14-71 23941062 56."/>
 <result pre="Fusi C. Trevisan G. Geppetti P. The TRPA1 channel in" exact="migraine" post="mechanism and treatment Br. J. Pharmacol. 2014 171 2552"/>
 <result pre="and SP in scalp arteries of patients suffering from chronic" exact="migraine" post="J. Neurol. Neurosurg. Psychiatry 2015 86 393 397 10.1136/jnnp-2014-308813"/>
 <result pre="A. Nemeth J. Szilvassy Z. Jancso G. Dux M. Diet-induced" exact="obesity" post="alters dural CGRP release and potentiates TRPA1-mediated trigeminovascular responses"/>
 <result pre="Lesaffre E. MaassenVanDenBrink A. de Hoon J. The influence of" exact="migraine" post="and female hormones on capsaicin-induced dermal blood flow Cephalalgia"/>
 <result pre="Mamontov O.V. Giniatullin R. Novel capsaicin-induced parameters of microcirculation in" exact="migraine" post="patients revealed by imaging photoplethysmography J. Headache Pain 2018"/>
 <result pre="Activation of meningeal nociceptors by cortical spreading depression: Implications for" exact="migraine" post="with aura J. Neurosci. 2010 30 8807 8814 10.1523/JNEUROSCI.0511-10.2010"/>
 <result pre="investigate the efficacy of the TRPV1 antagonist SB-705498 in acute" exact="migraine" post="Proceedings of the yje Pain in Europe VI Lisbon,"/>
 <result pre="M.F. Yarnitsky D. The development of cutaneous allodynia during a" exact="migraine" post="attack clinical evidence for the sequential recruitment of spinal"/>
 <result pre="the sequential recruitment of spinal and supraspinal nociceptive neurons in" exact="migraine" post="Brain J. Neurol. 2000 123 Pt 8 1703 1709"/>
 <result pre="Transient receptor potential vanilloid-4 has a major role in visceral" exact="hypersensitivity" post="symptoms Gastroenterology 2008 135 937 946 10.1053/j.gastro.2008.05.024 18565335 82."/>
 <result pre="et al. Genome-wide association study identifies novel susceptibility loci for" exact="migraine" post="in Han Chinese resided in Taiwan Cephalalgia 2018 38"/>
 <result pre="transient receptor potential V1 in the trigeminal system: Relevance to" exact="migraine" post="pathophysiology Cephalalgia 2018 38 833 845 10.1177/0333102417712719 28554243 93."/>
 <result pre="al. Genome-wide association study reveals three susceptibility loci for common" exact="migraine" post="in the general population Nat. Genet. 2011 43 695"/>
 <result pre="P. The TRPA1 channel in inflammatory and neuropathic pain and" exact="migraine" post="Rev. Physiol. Biochem. Pharmacol. 2014 167 1 43 24668446"/>
 <result pre="L. Johnson P.L. Oxford G.S. Hurley J.H. Induction of chronic" exact="migraine" post="phenotypes in a rat model after environmental irritant exposure"/>
 <result pre="of the transient receptor potential ankyrin type-1 (TRPA1) channel in" exact="migraine" post="pain: Evaluation in an animal model J. Headache Pain"/>
 <result pre="toxin type A in cranial dura: Implications for treatment of" exact="migraine" post="and other headaches Br. J. Pharmacol. 2016 173 279"/>
 <result pre="OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic" exact="migraine" post="Pain 2015 156 820 824 10.1097/j.pain.0000000000000119 25735000 131. Cady"/>
 <result pre="to acute interventions and preventative treatment with onabotulinumtoxinA in chronic" exact="migraine" post="Headache 2014 54 269 277 10.1111/head.12250 24147647 132. Shimizu"/>
 <result pre="J.E. Saper J.R. Intranasal civamide for the acute treatment of" exact="migraine" post="headache Cephalalgia 2000 20 597 602 10.1046/j.1468-2982.2000.00088.x 11075845 Figure"/>
 <result pre="TRP channels on trigeminal afferents and their potential role in" exact="migraine" post="pathology. Multiple TRP channels are expressed on trigeminal sensory"/>
 <result pre="which may also contribute to signaling within this circuit. Multiple" exact="migraine" post="therapeutics may act in this circuit, including: BoNTA, which"/>
</results>
